Experimental Immune-Boosting drug now available for bone cancer patients
NCT ID NCT04571229
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers L-MTP-PE, an investigational drug that activates white blood cells to fight cancer, to people with osteosarcoma. Eligible patients include those with newly diagnosed or relapsed osteosarcoma who have had surgery to remove all detectable cancer. The drug is given as an infusion over 36 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
L-MTP-PE (a drug that activates white blood cells to help the immune system kill cancer cells)
What this could lead to
If it works, this could provide a treatment option for people with osteosarcoma, especially those who have not responded to standard therapies.
What could go wrong
This is an expanded access program, not a formal trial, so effectiveness is not proven. The drug is still investigational and may not work for everyone. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
AVAILABLENew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••